# Nuclide record clarity-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/clarity-pharmaceuticals/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "clarity-pharmaceuticals" ;
  schema:name "Clarity Pharmaceuticals"@en ;
  schema:description "Clarity Pharmaceuticals, a Sydney radiopharmaceutical company, pairs copper isotopes with SAR-bisPSMA, a molecule that binds PSMA on prostate cancer cells: copper-64 for PET imaging, in the phase 3 AMPLIFY and CLARIFY trials, and copper-67 for therapy in the SECuRE trial. The copper-67 therapy is still at the dose-finding stage."@en ;
  schema:url <https://nuclide.cc/companies/clarity-pharmaceuticals/>, <https://www.claritypharmaceuticals.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.prnewswire.com/news-releases/clarity-pharmaceuticals-announces-secure-trial-update-on-8-gbq-67cu-sar-bispsma-dose-level-with-two-additional-complete-responses-302843184.html> ;
  schema:addressCountry "AU" ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/cu-64/>, <https://nuclide.cc/isotopes/cu-67/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:terms <https://nuclide.cc/terms/theranostics/> ;
  nuclide:trials <https://nuclide.cc/trials/nct04868604/> .